| __timestamp | Regeneron Pharmaceuticals, Inc. | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1271353000 | 15635076 |
| Thursday, January 1, 2015 | 1620577000 | 23943601 |
| Friday, January 1, 2016 | 2052295000 | 23689111 |
| Sunday, January 1, 2017 | 2075142000 | 41006114 |
| Monday, January 1, 2018 | 2186100000 | 51379106 |
| Tuesday, January 1, 2019 | 3036600000 | 32705593 |
| Wednesday, January 1, 2020 | 2735000000 | 53274000 |
| Friday, January 1, 2021 | 2908100000 | 85352000 |
| Saturday, January 1, 2022 | 3592500000 | 51999000 |
| Sunday, January 1, 2023 | 4439000000 | 59471000 |
| Monday, January 1, 2024 | 5132000000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. has consistently outpaced Summit Therapeutics Inc. in R&D investment. From 2014 to 2023, Regeneron's R&D expenses surged by approximately 250%, peaking at $4.4 billion in 2023. This robust growth underscores Regeneron's strategic focus on pioneering new treatments and therapies.
In contrast, Summit Therapeutics Inc. has maintained a more modest R&D budget, with expenditures increasing by around 280% over the same period, reaching nearly $59 million in 2023. While Summit's growth rate is impressive, the absolute scale of investment highlights the differing strategies of these two companies. As the biotech landscape evolves, these R&D investments will likely play a crucial role in shaping the future of healthcare innovation.
Research and Development: Comparing Key Metrics for Johnson & Johnson and Summit Therapeutics Inc.
Comparing Innovation Spending: Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Regeneron Pharmaceuticals, Inc. or Catalyst Pharmaceuticals, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. or Mesoblast Limited: Who Invests More in Innovation?
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Research and Development Expenses Breakdown: Alnylam Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Summit Therapeutics Inc. vs Exelixis, Inc.: Strategic Focus on R&D Spending
Summit Therapeutics Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Summit Therapeutics Inc. vs Catalyst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Summit Therapeutics Inc. and Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Summit Therapeutics Inc. and Taro Pharmaceutical Industries Ltd.